An aerosol generator for generating an inhalation aerosol from an inhalation liquid, includes an intake duct for guiding air to a mouth of a user, and a nozzle, arranged in the intake duct for injecting the inhalation liquid into the intake duct. The nozzle is arranged for generating a Rayleigh droplet train of the inhalation liquid propagating along a droplet train propagation path. The intake duct includes at least two first orifices having at least partly opposing discharging directions extending towards the droplet train propagation path. The at least two first orifices are configured for providing respective first air streams in at least partly opposing directions so as to interact in the droplet train propagation path.

An aerosol generator for generating an inhalation aerosol from an inhalation liquid, includes an intake duct for guiding air to a mouth of a user, and a nozzle, arranged in the intake duct for injecting the inhalation liquid into the intake duct. The nozzle is arranged for generating a Rayleigh droplet train of the inhalation liquid propagating along a droplet train propagation path. The intake duct includes at least two first orifices having at least partly opposing discharging directions extending towards the droplet train propagation path. The at least two first orifices are configured for providing respective first air streams in at least partly opposing directions so as to interact in the droplet train propagation path.

Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (C.sub.max) of at least 750 pg/ml, (b) with a mean time to C.sub.max (T.sub.max) of DHE of less than 45 minutes, and (c) a mean plasma AUC.sub.0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

The invention relates to an internal seal system. The internal seal may be incorporated into a pre-filled, small-volume nebulizer assembly with a T-connector. The small-volume nebulizer may be pre-filled with at least one unit-dose of medicine and hermetically sealed until use by an input port seal and the internal seal. The internal seal may operate as a valve when the assembly is changed into a second configuration.

This disclosure describes example antimicrobial compositions that may be used in combination with IV port cleansing caps, protective caps, or both. According to another implementations, the disclosure describes various cap devices that may be used in combination with the antimicrobial composition to cleanse, sanitized, and/or disinfected a surface.

This disclosure describes example antimicrobial compositions that may be used in combination with IV port cleansing caps, protective caps, or both. According to another implementations, the disclosure describes various cap devices that may be used in combination with the antimicrobial composition to cleanse, sanitized, and/or disinfected a surface.

The invention relates to an internal seal system. The internal seal may be incorporated into a pre-filled, small-volume nebulizer assembly with a T-connector. The small-volume nebulizer may be pre-filled with at least one unit-dose of medicine and hermetically sealed until use by an input port seal and the internal seal. The internal seal may operate as a valve when the assembly is changed into a second configuration.

A nasal delivery device for and a method of delivering substance to a nasal airway of a subject, the nasal delivery device including: a mouthpiece (519) through which the subject in use exhales to cause closure of the oropharyngeal velum of the subject; a nosepiece (517) for fitting to a nostril of a subject, the nosepiece including a nozzle (549) through which substance is in use delivered to the nasal airway; and a manually-actuatable substance supply unit (520) for delivering substance through the nozzle of the nosepiece.

A nasal delivery device for and a method of delivering substance to a nasal airway of a subject, the nasal delivery device including: a mouthpiece (519) through which the subject in use exhales to cause closure of the oropharyngeal velum of the subject; a nosepiece (517) for fitting to a nostril of a subject, the nosepiece including a nozzle (549) through which substance is in use delivered to the nasal airway; and a manually-actuatable substance supply unit (520) for delivering substance through the nozzle of the nosepiece.

This disclosure describes example antimicrobial compositions that may be used in combination with IV port cleansing caps, protective caps, or both. According to another implementations, the disclosure describes various cap devices that may be used in combination with the antimicrobial composition to cleanse, sanitized, and/or disinfected a surface.